Despite this, we propose that RAC1 and RAC1B could contribute to cetuximab resistance in CRC based on the known pathways that RAC1 and RAC1B activate that are related to known cetuximab resistance mechanisms. This evidence concerns the gene RAC1 and colorectal carcinoma.